BERNSTEIN：中国医药与生物科技-中国医药及生物科技领域 2025 年美国临床肿瘤学会（ASCO）会议第三部分

5 June 2025 China Pharma and Biotech China Pharma & Biotech: ASCO 2025 Part 3 - positive updates from IBI363, ZL-1310, and SHR-1826; review of highlights Rebecca Liang, Ph.D. +852 2123 2656 rebecca.liang@bernsteinsg.com Haopeng Zhou +852 2123 2630 haopeng.zhou@bernsteinsg.com Extensive stage small cell lung cancer (ES-SCLC): Zai Lab provided further detail on ZL-1310 (DLL3 ADC) in 2L+ ES-SCLC at the oral session. In addition to the 68% ORR of the dose escalation group (n=28), there were notable results in t ...